Comparative Pharmacology
Head-to-head clinical analysis: ETHRANE versus HALOTHANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHRANE versus HALOTHANE.
ETHRANE vs HALOTHANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
None Documented
None Documented
Clinical Note
moderateHalothane + Torasemide
"The risk or severity of adverse effects can be increased when Halothane is combined with Torasemide."
Clinical Note
moderateHalothane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid."
Clinical Note
moderateHalothane + Furosemide
"The risk or severity of adverse effects can be increased when Halothane is combined with Furosemide."
Clinical Note
moderateHalothane + Bumetanide
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Halothane is combined with Bumetanide."